Clinicopathological analysis of PD-L2 expression in colorectal cancer

Autor: Huijun Lai, Pingping Wu, Jing Sun, Peng-Da Guo, Jie Yang, Zhongwen Sun, Yundi Guo
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Zdroj: OncoTargets and therapy
ISSN: 1178-6930
Popis: Peng-Da Guo,1,* Zhong-Wen Sun,1,* Hui-Jun Lai,2 Jie Yang,1 Ping-Ping Wu,1 Yun-Di Guo,1 Jing Sun1 1Institute of Medical Technology, Suzhou Vocational Health College, Suzhou, Jiangsu 215009, China; 2Department of Ultrasound, Suzhou Traditional Chinese Medicine, Suzhou, Jiangsu 215007, China*These authors contributed equally to this workBackground: (PD-L2), a ligand of programmed cell death protein 1 (PD-1), is an inhibitory receptor of T cells and activated B cells. Many studies have focused on PD-L1, another ligand of PD-1, and the prognostic significance of PD-L1 has been reported in many tumors. However, the expression of PD-L2 in relation to clinical outcomes has not been fully investigated in cancer patients.Patients and methods: In this study, we investigated the expression of PD-L2 via immunohistochemistry (IHC) in the pathological specimens of 348 patients treated for colorectal cancer (CRC).Results: Strong PD-L2 expression was found in the cancer tissues from 41% of the CRC patients who also had a high TNM stage and carcinoembryonic antigen (CEA) concentration. We also carried out functional studies in vitro, which showed that PD-L2 did not influence the growth of the CRC cell line HCT116, but increased cell invasion.Conclusion: Collectively, these findings suggest that PD-L2 may be a potential therapeutic target for CRC.Keywords: PD-L2, colorectal cancer, migration, therapeutic target
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje